Mountain View, CA, United States of America

Keith Roger Bley

USPTO Granted Patents = 6 

Average Co-Inventor Count = 6.3

ph-index = 2

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2001-2006

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Keith Roger Bley: Innovator in Pharmaceutical Chemistry

Introduction

Keith Roger Bley is a notable inventor based in Mountain View, CA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that act as IP receptor antagonists. With a total of 6 patents to his name, Bley has established himself as a key figure in his area of expertise.

Latest Patents

Among his latest patents, Bley has developed innovative compounds such as 2-(substituted-phenyl)amino-imidazoline derivatives. This invention relates to IP receptor antagonists selected from a specific group of compounds represented by a defined formula, including their pharmaceutically acceptable salts or crystal forms. Additionally, he has worked on thiophenylaminoimidazolines as IP antagonists, which involve methods for treating diseases mediated by IP antagonists through the administration of specific compounds.

Career Highlights

Throughout his career, Keith Roger Bley has worked with prominent companies in the pharmaceutical industry, including Syntex Inc. and Roche Palo Alto LLC. His work has contributed to advancements in therapeutic agents and pharmaceutical compositions.

Collaborations

Bley has collaborated with notable colleagues such as Robin D. Clark and Alam Jahangir, further enhancing his contributions to the field.

Conclusion

Keith Roger Bley is a distinguished inventor whose work in pharmaceutical chemistry has led to the development of important therapeutic agents. His innovative patents and collaborations reflect his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…